Pan-cancer analysis

Natera to Present New Signatera™ MRD Data at ESMO 2023, Featuring Large, Updated Analysis from CIRCULATE-Japan Study

Retrieved on: 
Monday, October 16, 2023
Other Health, Health, Genetics, Health Technology, Oncology, Congress, DFS, Neoplasm, Doctor of Philosophy, Hepatocellular carcinoma, NTRA, Nature Medicine, Abstract, LARC, Master of Science, RCC, DNA, Survival, CRC, Cancer, Recurrence, Disease, Renal cell carcinoma, Colorectal cancer, European Society for Medical Oncology, ESMO, AA, Pan-cancer analysis, ECD, MRD, Cohort (statistics), HCC, Patient, BTC, Pharmaceutical industry, Medical imaging, Aroma compound, MD, Natera

Natera and its collaborators will present MRD data in a total of seven abstracts, including a mini-oral and several poster presentations.

Key Points: 
  • Natera and its collaborators will present MRD data in a total of seven abstracts, including a mini-oral and several poster presentations.
  • Other presentations will highlight new Signatera data in rectal cancer, appendiceal adenocarcinoma, hepatocellular carcinoma, renal cell carcinoma, and other solid tumors.
  • “We look forward to the presentation of updated data from the landmark CIRCULATE-Japan study.
  • Presentation #1908P | Renal Cancer | Oct. 23 | Presenter: Michael Smigelski, MD
    This study demonstrates that longitudinal ctDNA monitoring may be predictive of recurrence-free survival post-surgery in patients with RCC.

Pan Cancer T appoints Rachel Abbott to succeed Katrien Reynders-Frederix as Chief Executive Officer

Retrieved on: 
Friday, May 12, 2023
TNBC, CSO, Supervisory board, Erasmus MC, PCT, TCR, Entrepreneurship, Pan-cancer analysis, Patient, Supervision, Management, Medical imaging

ROTTERDAM, May 12, 2023 - Pan Cancer T B.V. , a biotech spin-off from Erasmus MC dedicated to the discovery and development of next-generation TCR-T therapies against solid tumors, today announces the appointment of Dr. Rachel Abbott as Chief Executive Officer (CEO).

Key Points: 
  • ROTTERDAM, May 12, 2023 - Pan Cancer T B.V. , a biotech spin-off from Erasmus MC dedicated to the discovery and development of next-generation TCR-T therapies against solid tumors, today announces the appointment of Dr. Rachel Abbott as Chief Executive Officer (CEO).
  • Rachel steps up from her current role as Pan Cancer T’s Chief Scientific Officer (CSO), succeeding Katrien Reynders-Frederix who has served as CEO since the company’s inception.
  • “I am very honoured to accept the Supervisory Board’s and shareholders’ offer to lead Pan Cancer T and I look forward to building on the strong foundation laid by Katrien,” said Rachel Abbott.
  • We look forward as a Supervisory Board to working with Rachel and supporting her in the transformation of PCT as a leading player in the field.”

Pan Cancer T Appoints Prof. Dr. Chiara Bonini to its Scientific Advisory Board

Retrieved on: 
Thursday, February 23, 2023
Transplant, School, British Rail Research Division, Cancer, TCR, Lymphocyte, Engineering, Infection, Pan-cancer analysis, Patient, Neoplasm, Hematology, Haematopoietic system, EMA, Medical school, Coronavirus Scientific Advisory Board, Gene editing, Erasmus MC, Vaccine

ROTTERDAM, February 23, 2023 - Pan Cancer T B.V., a biotech spin-off from Erasmus MC dedicated to the discovery and development of next-generation TCR-T therapies against solid tumors, today announced the appointment of Prof. Dr. Chiara Bonini to its Scientific Advisory Board.

Key Points: 
  • ROTTERDAM, February 23, 2023 - Pan Cancer T B.V., a biotech spin-off from Erasmus MC dedicated to the discovery and development of next-generation TCR-T therapies against solid tumors, today announced the appointment of Prof. Dr. Chiara Bonini to its Scientific Advisory Board.
  • She is a physician and researcher with an outstanding scientific track record and has been trained in hemato-oncology and immunology.
  • "We warmly welcome Chiara Bonini to our Scientific Advisory Board,” said Katrien Reynders-Frederix, CEO of Pan Cancer T. "Chiara brings remarkable scientific expertise and has been pioneering the development of T cell therapies in Europe.
  • "I am excited to join Pan Cancer T´s Scientific Advisory Board,” said Prof. Dr. Chiara Bonini.

Vizgen to Present New Capabilities and Data from the MERSCOPE™ Spatial Transcriptomics Platform at Advances in Genome Biology and Technology (AGBT) General Meeting

Retrieved on: 
Monday, February 6, 2023
Biotechnology, Medical Devices, Health, Genetics, Stem Cells, Biology, Neuroscience, Pan-cancer analysis, Oncology, RNA, Hepatocellular carcinoma, Map, Mass meeting, Disease, Inc., Gene expression, Microscope, Medical imaging, Partnership

With single-cell resolution, the MERSCOPE Platform accurately recapitulates known biology and identified rare cell types.

Key Points: 
  • With single-cell resolution, the MERSCOPE Platform accurately recapitulates known biology and identified rare cell types.
  • “The data we’re presenting at AGBT underscores the capabilities of Vizgen’s MERSCOPE Platform,” said Terry Lo, President and CEO of Vizgen.
  • This data represents the most comprehensive map of the mouse brain and describes the neuronal diversity underlying the anatomical and functional structures.
  • Presented By: George Emanuel, Ph.D., Scientific Co-founder, Sr. Director of Technology & Partnerships, Vizgen